Pharmicell Co (A005690) Q3 2025 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, specialty chemicals).

• No subsidiaries or affiliates as of the reporting date.

• Listed on KOSPI since 1988.

Financial highlights

• Revenue for 2025 Q3 YTD: KRW 79.4 billion, up from KRW 64.9 billion in 2024 and KRW 56.2 billion in 2023.

• Operating income for 2025 Q3 YTD: KRW 24.7 billion, up from KRW 7.1 billion in 2024 and KRW 4.7 billion in 2023.

• Net income for 2025 Q3 YTD: KRW 24.6 billion, up from KRW 6.3 billion in 2024 and KRW 3.6 billion in 2023.

• Cash and cash equivalents at period end: KRW 19.2 billion, up from KRW 8.3 billion at 2024 year-end.

Outlook and guidance

• Continued investment in R&D for stem cell therapies and pharmaceutical intermediates.

• Expansion of production capacity with new Ulsan Plant 3 (KRW 30 billion investment, 2025–2026).

• Ongoing clinical trials for new stem cell therapies (liver cirrhosis, erectile dysfunction, chronic kidney disease).